SEC Form 4 · accession 0001209191-19-003255
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Neumann
Officer — EVP, Chief Commercial Officer
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.73 | Jan 8, 2019 | A | 86,348 | A | — | Jan 7, 2029 | Common Stock | 86,348 | 86,348 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 8, 2019 | A | 62,843 | A | — | — | Common Stock | 62,843 | 62,843 | D |
Explanation of responses
- F1On January 8, 2019, the reporting person was granted options to purchase 86,348 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3On January 8, 2019, the reporting person was granted 62,843 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.